MediciNova (MNOV) Q1 2025 earnings summary

Executive summary

• Focus remains on developing MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic/metabolic diseases, with a commercial emphasis on the U.S. market.

• Accumulated deficit reached $429.6 million as of March 31, 2025, with expectations of continued net losses as development progresses.

• Strategy includes advancing programs via investigator-sponsored trials, grants, and potential strategic alliances.

Financial highlights

• Cash and cash equivalents were $36.6 million at March 31, 2025, down from $40.4 million at December 31, 2024.

• Net loss for Q1 2025 was $2.86 million, compared to $2.75 million in Q1 2024.

• Operating expenses totaled $3.20 million in Q1 2025, up slightly from $3.14 million in Q1 2024.

• Interest income decreased to $0.34 million from $0.40 million year-over-year, reflecting lower cash balances.

• Working capital stood at $35.5 million as of March 31, 2025.

Outlook and guidance

• Management believes current working capital is sufficient to fund operations through at least May 2026.

• Expects to incur substantial net losses for several years as development programs continue.